Europe Biopsy Devices Market

Europe Biopsy Devices Market Size (2022 to 2027)

The biopsy devices market size in Europe was worth USD 555.30 million in 2022 and is estimated to be growing at a CAGR of 7.1% to reach USD 782.49 million by 2027. Europe holds the second primary market for biopsy devices due to the acceptance of advanced technology in biotechnology and research and innovation technologies.

Biopsy devices are attaining importance due to the rising incidence of cancer and the growing willingness of patients to spend money on these medical procedures. Biopsies are generally performed to recognize and diagnose if the tumor is cancerous and then design a suitable treatment plan.

The European market for biopsy devices is mainly driven by the broader execution of national cancer screening programs, increased reimbursement coverage for biopsy processes, growing adoption of premium-priced devices, and favorable demographics. Although, low R&D expenses may boost the market share in emerging countries. An excessive pool of diseases and cancer populations points towards the rise in the market share of the emerging countries.

The increase in the number of cancer patients is driving the European biopsy devices market. European countries focus more on providing low-cost and better-quality treatment options and the rapid adoption of medical devices, surgical centers, and increasing awareness about the biopsy. It is boosting the European biopsy device market's growth. EU WHO develop programs for cancer control also coordinate & research on cause with strategic developments. Growth in the diagnostic centers, the better infrastructure of hospital facilities, and involvement in the R & D sector expand the biopsy devices market in the European region. The European government has started the CANCER-ID project. The project team focused on four mainstream through liquid biopsy testing for cancer. This project, funded by public partnerships between the Europe union & the European pharmaceutical industry, is covered by 38 industry partners from 13 European countries. This project may lead to the growth of the European biopsy devices market. Around 60% of coeliac disease patients have been diagnosed without a biopsy.

This research report on the European Biopsy Devices Market has been segmented & sub-segmented into the following categories:

By Product: 

• Instruments
  • Manual
  • Automated
  • Semi-automated
• Consumables
  • Reagents
  • Kits

By Type: 

• Needle Biopsy
  • core needle biopsy
  • fine-needle biopsy
  • vacuum-assisted biopsy
• Surgical Biopsy
  • Incisional biopsy
  • Excisional biopsy

By Application: 

• Scientific Research
• Medical Diagnosis
• Agricultural Applications
• Genetic Fingerprinting
• Sex Determination

By End User: 

• Pharmaceutical and Biology Industry
• Academic Research Institute
• Contract Research Organizations
• Forensic Labs

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Regionally, the German biopsy devices market is predicted to play a leading role in the European region during the forecast period. German researcher develops a liquid biopsy test for skin cancer detection, and the new technique makes screening faster for cancer patients. Germany has its own regulatory body, i.e., the Federal Joint Committee, and all decisions regarding any healthcare drugs & medical devices are taken by the committee. Germany is the largest medical device market, adopting the MRI, X-RAY guides practitioners, physicians, and biopsy. Germany, Agena Biosciences Company, is exploring the new technical biopsy devices in the market. German companies manufacture advanced biopsy devices over the world with higher efficiency in less time.

The European mammography division of GE Healthcare has performed the first breast cancer Angio- mammography by using the Pristina Serena biopsy robot on a patient. U.S. Food & Drug Administration gives clearance to Pristina Serena Bright™ for the treatment. France provides a large no. of skilled medical professionals for the biopsy; it gains market value towards the growth. 

Germany is leading the biopsy devices market in the European region. The country develops its research, which acts as a liquid biopsy test for detecting skin cancer, making quick and easy screening for patients. A growing number of cancer cases have become one of the most leading causes of death worldwide. In 2012, the occurrence rate of cancer was 14.1million and was estimated to grow up to 70.0% over the next 20years.

The biopsy devices market in Spain is expected to grow strongly over the upcoming years due to growing frequent occurring rare diseases like cancer and others. For example, in 2018, there were nearly 270 363 cases of cancer, and 113,584 deaths took place due to cancer.

The UK biopsy devices market is expected to hold a substantial share in the European market during the forecast period due to various cancers like prostate, breast, lung, colon, and skin, which are the most common types found in the UK. In 2018, nearly 446,942 new cancer cases were recorded in the UK.

The France biopsy devices market is forecasted to register a healthy CAGR from 2022 to 2027. The cancer occurrence rate has been increased from 1990 to 2018. In 1990, there were about 215,000 cancer cases escalated to 382,000 by 2018, which is estimated to drive growth for the biopsy devices market in France.

KEY MARKET PLAYERS:

Companies playing an essential role in the biopsy devices market in Europe region profiled in this report are Medtronic, Leica Biosystems, Hologic Inc., Boston Scientific Corporation, Becton, Cook Medical Inc., C.R. Bard Inc., Mauna Kea Technologies, Ethicon EndoSurgery Inc., Veran Medical Technologies, Dickinson and Company, Fujifilm Medical Systems, MDxHealth, Argon Medical Devices Inc and Intact Medical Corp.